Lactobacillus sakei is a food bacterium sold as a refrigerated powder and administered intranasally for long-running sinus inflammation. Nasal use has almost no human evidence that symptoms change. The case is how it might work, plus a mouse result in which one strain limited injury; a later lab study found a human-nose strain did not reseal a leaky lining. Uncertainty sits on symptoms, not on a settled verdict. (Full Review)
| Marker | Target | Why |
|---|---|---|
| SNOT-22 | No organism-specific target. Change from the person's own baseline; a drop of at least 9 points is a widely cited noticeable change. About 12 points has been proposed for medicine-treated sinusitis. Neither number was derived for this organism. | Sinus symptom burden |
| Body temperature | No functional target. The person's own baseline and any new fever. Conventional fever cutoff is 38.0 °C. Any new fever is a reason to stop, not a dosing goal. | Early flag for invasive infection |
| Nasal comfort after application | No numeric target. New burning, bleeding, or sneezing. | Local irritation from a topical dose |
| Days that an antibiotic or a steroid spray was used | No numeric target | Practical flare count |
Cadence: Baseline before a nasal or oral course, again at about 2 weeks and at 4 to 6 weeks, then only if symptoms return.